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To compare the real-world effectiveness of newer disease-modifying therapies (DMTs) vs
injectables in children with relapsing-remitting multiple sclerosis (RRMS).
Methods
In this retrospective, multicenter study, from the UK Childhood Inflammatory Demyelination
Network, we identified children with RRMS receiving DMTs from January 2012 to December
2018. Clinical and paraclinical data were retrieved from the medical records. Annualized relapse
rates (ARRs) before and on treatment, time to relapse, time to newMRI lesions, and change in
Expanded Disability Status Scale (EDSS) score were calculated.
Results
Of 103 children treated with DMTs, followed up for 3.8 years, relapses on treatment were
recorded in 53/89 (59.5%) on injectables vs 8/54 (15%) on newer DMTs. The ARR was
reduced from 1.9 to 1.1 on injectables (p < 0.001) vs 1.6 to 0.3 on newer DMTs (p = 0.002).
New MRI lesions occurred in 77/89 (86.5%) of patients on injectables vs 26/54 (47%) on
newer DMTs (p = 0.0001). Children on newer DMTs showed longer time to relapse, time to
switch treatment, and time to new radiologic activity than patients on injectables (log-rank p <
0.01). After adjustment for potential confounders, multivariable analysis showed that inject-
ables were associated with 12-fold increased risk of clinical relapse (adjusted hazard ratio [HR]
= 12.12, 95% CI = 1.64–89.87, p = 0.015) and a 2-fold increased risk of new radiologic activity
(adjusted HR = 2.78, 95% CI = 1.08–7.13, p = 0.034) compared with newer DMTs. At 2 years
from treatment initiation, 38/103 (37%) patients had MRI activity in the absence of clinical
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Conclusion
Newer DMTs were associated with a lower risk of clinical and radiologic relapses in patients compared with injectables. Our study
adds weight to the argument for an imminent shift in practice toward the use of newer, more efficacious DMTs in the first instance.
Classification of Evidence
This study provides Class IV evidence that newer DMTs (oral or infusions) are superior to injectables (interferon beta/
glatiramer acetate) in reducing both clinical relapses and radiologic activity in children with RRMS.
Pediatric multiple sclerosis (MS) has an incidence ranging
between 0.13 and 0.66 per 100,000 children per year.1 In
comparison to MS in adults, pediatric MS is associated with a
higher relapse rate2 and rapid MRI lesion accrual early in the
disease course,3 with worse cognitive outcomes4 and physical
disability in the long term. Furthermore, patients show pro-
gressive brain atrophy, especially in the gray matter.5 Despite
a highly active disease, particularly in the initial years, patients
with pediatric-onset MS demonstrate a slower rate of accrual
of disability compared with adult-onset patients.6
The approach to treatment of relapsing-remitting multiple
sclerosis (RRMS) is rapidly evolving, with 15 disease-modifying
therapies (DMTs) currently licensed for adults, that target the
immune system peripherally and reduce MS relapse risk.7 These
range from injectables (interferon-β and glatiramer acetate), with
favorable side effect profiles but moderate clinical efficacy, to
newer oral or infusion DMTs, associated with greater treatment
efficacy, but a higher risk profile.8 Current treatment strategies in
pediatric MS are largely center specific and reliant on adult
protocols; there is a clear need to balance the risk of under-
treating children causing poor disease control and accrual of
motor, visual, and cognitive disabilities or overtreating them,
particularly with sequential immunotherapy, exposing the child
to unnecessary toxic effects, which may include reduced fertility,
malignancy risks, and premature immune senescence.9 Never-
theless, an improvement in prognosis with a globally reduced
annualized relapse rate in children with MS is observed com-
pared with the pretreatment era,10 indicating a possible long-
term effect of therapies. In a multicenter observational study of
741 pediatric patients with MS from the US Network of Pedi-
atric MS Centers, those on newer DMTs had lower relapse rates
(rate difference = 0.27, p = 0.004) and lower rates of new/
enlarging T2 (hazard ratio [HR] = 0.51, p < 0.001) and
gadolinium-enhancing lesions (HR= 0.38, p < 0.001) than those
on injectables.11 The results of the first pediatricMS randomized
controlled trial of fingolimod (newer oral DMT) vs interferon-β
(older injectable DMT) demonstrated the superiority of fingo-
limod over interferon-β, with a lower relapse rate, less accumu-
lation of lesions on MRI, and a lower annualized rate of brain
atrophy over a 2-year period.12,13
There are very few studies to guide optimal initial DMT choice
for pediatric MS. We therefore aimed to evaluate real-world
effectiveness of treatment with newer compared with injectable
DMTs in children with RRMS. In addition, we aimed to
compare the different clinical (annualized relapse rate [AAR]),
imaging (≥2 new T2 hyperintense and/or ≥1 gadolinium-
enhancing lesions), and disability parameters (Expanded Dis-
ability Status Scale [EDSS] score) before and on treatment.
Methods
This project was a multi-institutional, retrospective study run
within the UK Childhood Inflammatory Demyelination
Network, involving 7 pediatric neuroscience centers com-
missioned to manage pediatric-onset MS: Great Ormond
Street Hospital (London), Evelina London Children’s Hos-
pital (London), Birmingham Children’s Hospital, Adden-
brooke’s Hospital (Cambridge), Alder Hey Children’s
Hospital (Liverpool), Royal Manchester Children’s Hospital,
and Great North Children’s Hospital (Newcastle). Centers
were asked to identify patients aged <18 years with RRMS
receiving DMTs in the period of January 2012 to December
2018, using Blueteq records of DMT prescriptions (drug
management system used by NHS England for high-cost
drugs including DMTs).14 Patients who entered a clinical trial
with a DMT were excluded. Clinical data including de-
mographics, clinical findings and laboratory results, first and
subsequent relapse characteristics, and treatment information
were retrospectively reviewed from electronic medical records
of patients and entered into a standardized database.
All patients had undergone brain imaging according to local MRI
protocols every 6 months with a new baseline MRI once com-
menced on new treatment. Spinal cord imaging was only per-
formedwhen clinically indicated andwas not performed routinely.
The patient’s age at DMT start, year the DMTwas prescribed,
duration of use, side effects, and reasons for discontinuation
or switching therapies were included. The NCI Common
Terminology Criteria for Adverse Events (v.5) were used for
reporting of adverse events using a grading (severity) scale.15
Glossary
ARR = annualized relapse rate; DMT = disease-modifying therapy; EDSS = Expanded Disability Status Scale; HR = hazard
ratio; IQR = interquartile range; MS = multiple sclerosis; RRMS = relapsing-remitting multiple sclerosis.
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Markers of disease severity included first relapse characteristics
(polysymptomatic, transverse myelitis, and optic neuritis),
number of relapses and presence of new T2 hyperintense or
gadolinium-enhancing lesions on brain MRI before treatment
and on treatment, and EDSS scores at baseline and last follow-up.
DMTs classified as newer included dimethyl fumarate, fingo-
limod, teriflunomide, natalizumab, ocrelizumab, and alemtu-
zumab. DMTs were also classified by mode of administration,
including injectables (glatiramer acetate and interferon-β), oral
(dimethyl fumarate, fingolimod, and teriflunomide), or in-
fusion (natalizumab, ocrelizumab, and alemtuzumab). The
primary comparison was between patients on injectables and
those who were started on or escalated to newer DMTs (oral
and infusions).
The following outcome measures were calculated: (1) ARRs
before and on treatment, (2) time to clinical relapse from
treatment initiation (relapses are defined as new/worsening
neurologic symptoms lasting at least 24 hours in the absence
of fever or infection, as determined by the treating neurolo-
gist), (3) time to switching DMT from treatment initiation,
(4) time to development of ≥2 new T2 hyperintense and/or
≥1 gadolinium-enhancing lesions on brain MRI from treat-
ment imitation, and (5) change in EDSS score from baseline
to last follow-up on treatment.
ARRs were calculated as the number of relapses per year
before treatment (excluding index event) and during treat-
ment only in patients with at least 6 months of follow-up after
initiation of treatment. An attack was defined as “definitely
Table Demographics, Baseline, and Follow-up Clinical and Radiologic Features Stratified to Patients Starting Injectables
(n = 89) and Newer DMTs (n = 14) as Their First-Line Therapy
All patients with
MS (N = 103)
Patients starting
injectables (n = 89)
Patients starting newer
DMTs (n = 14) p Value
Age at presentation (yrs), median (IQR) 14.0 (12.0–14.8) 13.9 (11.9–14.6) 14.3 (12.9–15.1) 0.42
Sex (M:F) 1 : 2.7 24:64 (1:2.7) 3:11 (1; 3.7) 0.65
Ethnicity (White:other) 1 : 1.1 49:40 (1.3:1) 2:12 (1:6) <0.005
CIS phenotype at onset
Optic neuritis 27 (26%) 26 (29%) 1 (7%)
Transverse myelitis 4 (4%) 4 (45%) 0 (0%)
Polysymptomatica 72 (70%) 61 (69%) 11 (79%)
Intrathecal oligoclonal bands 87/93 (95%) 79/83 (95%) 8/10 (80%) 0.06
Abnormal MRI at onset 102 (99%) 88 (99%) 14 (100%) 0.69
Locations of MRI lesions at onset
Periventricular 95 (94%) 81 (91%) 14 (100%)
Infratentorial 76 (74%) 66 (74%) 10 (71%)
Cortical/juxtacortical 75 (73%) 67 (75%) 8 (57%)
Spinal cord 60 (59%) 51 (57%) 9 (64%)
New MRI lesions over time 92 (89%) 86 (97%) 6 (43%) <0.0001
Locations of new MRI lesions
Periventricular 100 (97%) 87 (98%) 13 (93%)
Infratentorial 96 (93%) 82 (92%) 14 (100%)
Cortical/juxtacortical 89 (86%) 79 (89%) 10 (71%)
Spinal cord 81 (79%) 75 (84%) 6 (43%)
No of relapses before DMT, median (IQR) 2 (1–3) 2 (1–3) 1 (1.5–2) 0.67
Time from initial presentation to DMT, median (IQR) 1.2 (0.7–2.0) 1.0 (0.6–1.9) 1.8 (1.4, 2.5) 0.50
Baseline EDSS score before DMT, median (IQR) 1.0 (0–1.5) 1.0 (0–1.5) 1.0 (0.25–1.5) 0.94
EDSS score at last follow-up, median (IQR) 1.0 (1–1.5) 1.0 (1–1.5) 1.0 (1–1.5) 0.83
Abbreviations: DMT = disease-modifying therapy; EDSS = Expanded Disability Status Scale; IQR = interquartile range; MS = multiple sclerosis.
a This category includes brainstem, cerebellar, and other presentations.
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new neurologic symptom” or “clear acute worsening of pre-
vious neurologic deficits” with objective clinical signs, lasting
for at least 24 hours and attributed to an inflammatory CNS
event, confirmed by the treating physician. Relapses were
analyzed for up to 2 years before initiation of therapy and for
the duration of the time undergoing therapy.
Statistical Analysis
Descriptive statistics were performed on the demographic and
clinical variables. Mean, median, SD, and interquartile range
(IQR) were reported as appropriate. A paired 2-tailed t test was
used to compare ARRs before and on treatment. Kaplan-Meier
survival analyses were used to estimate the cumulative risk of
clinical relapses on treatment, of switching treatment, and of the
development of ≥2 newT2 hyperintense and/or ≥1 gadolinium-
enhancing lesions on brain MRI, using the log-rank test to
compare patients starting injectables (n = 89) and those starting
newer DMTs (n = 14). Kaplan-Meier survival analyses were also
used to estimate the cumulative risk of clinical relapses, ≥2 new
MRI lesions, and EDSS score worsening for all 103 children in
our cohort. In addition, we built Cox proportional hazards
models to investigate the impact of DMT choice (newer vs
injectables) on the risk of clinical relapses, risk of switching
treatment, and risk of the development of ≥2 new T2 hyperin-
tense and/or ≥1 gadolinium-enhancing lesions on brain MRI,
after adjusting for potential confounders including sex, ethnicity,
age at presentation and DMT initiation, relapse characteristics at
presentation (optic neuritis, transverse myelitis, and poly-
symptomatic), number of relapses in the prior 6 months, and
EDSS score at baseline before treatment. For each analysis
performed, adjusted HRs are reported for DMT type.
For MRI outcome, we used midpoint survival analyses due to
the fact that there is variation in the timing of MRI scans in
clinical practice and the actual time of a new lesion developing
is not known. Therefore, we used the midpoint of time be-
tween the MRI with a new lesion and previous MRI to esti-
mate when the new lesion developed. For time to ≥2 new T2
hyperintense and/or ≥1 gadolinium-enhancing lesions anal-
ysis, we included patients if they had a baseline brain MRI
within the 6 months before starting a DMT, as well as ≥1MRI
midpoint during treatment on that DMT. Results associated
with a value of p < 0.05 were considered significant. Data were
analyzed with GraphPad Prism 8 (GraphPad Software) and
StataSE version 14 (StataCorp LLC, College Station, TX).
Standard Protocol Approvals, Registrations,
and Patient Consents
This study was approved by Great Ormond Street Hospital
Research and Development Department (reference: 16NC10).
Data Availability
For purposes of replicating procedures and results, any
qualified investigator can request anonymized data after ethics
clearance and approval by all authors.
Results
A total of 103 children with a diagnosis of RRMS who re-
ceived treatment with a DMT were identified. Median age at
symptom onset was 14.0 years (IQR 12.0–14.8 years). Clin-
ical features and patient demographics are summarized in the
table. The median length of follow-up from first clinical pre-
sentation was 3.8 years (IQR 3–7 years) and from DMT
initiation was 2.8 years (IQR 2.1–3.6 years).
Sixty-three (61%) patients were treated with 1 DMT, 37
(36%) were treated with 2 DMTs, and 3 (3%) were treated
Figure 1 Patient Disease-Modifying Therapy (DMT) Pathway
Patients were distributed across treatment cen-
ters as follows; 45 (44%) at Great Ormond Street
Hospital, 25 (24%) at Evelina Children’s Hospital,
18 (18%) at Birmingham Children’s Hospital, 5
(5%) at Royal Manchester Children’s hospital, 4
(4%) at Great North Children’s Hospital, 3 (3%) at
Addenbrooke’s Hospital, and 3 (3%) at Alder Hey
Children’s Hospital. Of the 103 children included,
89 patients (86%) were started on an injectable as
their first DMT (interferon-β [n = 73] and glatir-
amer acetate [n = 14]), and 14 (14%) were started
on a newer DMT (dimethyl fumarate [n = 7], fin-
golimod [n = 4], natalizumab [n = 2], and alem-
tuzumab [n = 1]). Three of the 89 patients (3%) on
injectables switched to another injectable (in-
terferon-β [n = 1] and glatiramer acetate [n = 2]),
of which 2 were then escalated to a newer DMT
(fingolimod [n = 1] and alemtuzumab [n = 1]).
Thirty five of 89 (39%) children who started on
injectables were escalated to a newer DMT (fin-
golimod [n = 14], natalizumab [n = 13], dimethyl
fumarate [n = 5], teriflunomide [n = 2], and
ocrelizumab (n = 1)), of which 1 switched to an-
other newer DMT (fingolimod [n = 1]). Two of the
14 patients who were started on a newer DMT as
their first drug switched to another newer DMT
(fingolimod [n = 2]).
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with 3 or more DMTs. Figure 1 describes the DMT pathway
for all 103 patients included. Patients had a median of 2 re-
lapses (range 1–5) before starting treatment. The median
time from initial presentation to starting injectables was 1.0
years (IQR 0.6–1.9 years), whereas from initial presentation
to starting a newer DMT was 1.8 years (IQR 1.4–2.5 years).
Of the 305 clinical relapses reported in the cohort, 113 of
these (37%) occurred while patients were on treatment.
The annualized relapse rate (ARR) reduced from 1.9 to 1.1
while on interferon-β and glatiramer acetate (n = 89, p <
0.001). The ARR was reduced from 1.7 to 0.4 for newer
DMTs when used as first medication (n = 14, p = 0.02). For
newer DMTs used as second- and third-line treatment, the
ARR was reduced from 1.6 to 0.2 (n = 40, p = 0.003).
Overall, when considering all patients on newer DMTs
(either starting on, or escalating to newer DMTs), ARR was
reduced from 1.6 to 0.3 (n = 54, p = 0.002). For individual
newer DMTs, ARR reduction before and on treatment was
as follows: 1.1 to 0.7 with dimethyl fumarate (n = 12, p =
0.3), 1.9 to 0.3 with fingolimod (n = 21, p = 0.01), 1.7 to 0.3
with natalizumab (n = 15, p = 0.04), 0.5 to 0.5 with teri-
flunomide (n = 2, p = 0.5), and 1.2 to 0 with alemtuzumab (n
= 2, p = 0.1) (figure 2; figure e-1, links.lww.com/NXI/
A492). For the 40 patients who escalated from injectables to
newer DMTs, there was an overall reduction of ARR from
1.7 to 0.2 (p = 0.0001).
Relapses on treatment were recorded in 53/89 (59.6%) of
patients who had an injectables compared with 8/54 (15%)
children who started on or escalated to newer DMTs. Of note,
20 patients (19.4%) who relapsed on treatment were not
escalated; of these, 13 were on injectables and 7 were on
newer DMTs. Kaplan-Meier survival analysis showed longer
time to first relapse in children on newer DMTs. compared
with injectables (log-rank p < 0.001) (figure 3A) and a longer
time to switching treatment in children on newer DMTs
compared with injectables (log-rank p = 0.0016) (figure 3C).
During the period, a median of 4 (range 3–10) repeated MRI
scans were performed. Radiologic activity occurred in 77/89
(86.5%) of patients who had injectables compared with 26/54
(47%) who started on or escalated to newer DMTs. Kaplan-
Meier survival analysis showed children on newer DMTs had
longer time to developing of ≥2 new T2 hyperintense and/or
≥1 gadolinium-enhancing lesions compared with those on
injectables (log-rank p = 0.002) (figure 3B). Median time to
new radiologic activity was 2.8 years (IQR 0.5–2.0 years) on
newer DMTs compared with 1.8 years (IQR 0.8–3.2 years)
on injectables. Overall, clinical relapses occurred in 53/103
(51%) patients and new MRI lesions occurred in 91/103
(88%) patients at 2 years from treatment initiation. In fact, at
2 years, 38/103 (37%) patients had ≥2 new T2 hyperintense
and/or ≥1 gadolinium-enhancing lesions in the absence of
clinical relapses.
Baseline and follow-up EDSS scores during treatment were
available for all children; the median EDSS score at baseline
before treatment initiation was 1.0 (IQR 0–1.5), and at last
follow-up on treatment was 1.0 (IQR 1–1.5). In total, only 10
children (9.7%) had an EDSS score ≥2 before treatment
initiation, and this increased to 12 (11.7%) children at last
follow-up. EDSS worsening ≥1.0 point was observed in 12
children (13%) on injectables compared with 7 children
(13%) who were started or escalated to newer DMTs. Of 88
children with cognitive assessments reported, only 2 (2%) had
cognitive impairment, as defined by impairment in 3 separate
domains on testing.16
We performed multivariable analysis and adjusted our results
for the variables that have been identified as potential con-
founders, showing that starting on injectables was associated
with a twelvefold increased risk of clinical relapse (adjusted
HR = 12.12, 95% CI = 1.64–89.87, p = 0.015) and a twofold
increased risk of new radiologic activity (adjusted HR = 2.78,
95% CI = 1.08–7.13, p = 0.034) compared with starting on
newer DMTs. For patients starting injectables, there was no
increased risk of switching treatment (adjusted HR = 0.96,
95% CI = 0.28–3.29, p = 0.94) compared with those starting
on newer DMTs.
Kaplan-Meier survival analysis demonstrated that the pro-
portion of patients with ≥2 new T2 hyperintense and/or ≥1
gadolinium-enhancing lesions was higher than the proportion
who had clinical relapses and EDSS score increase ≥1
throughout follow-up (figure 4).
Side effects were reported by 55/89 patients (61.8%) on in-
jectables, of which 50 were grade 1 adverse events on the
CTCAE grading scale,15 and 5 were grade 2. The most
commonly reported side effects for injectables were flu-like
Figure 2 Annualized Relapse Rates Before and on Treatment
Annualized relapse rates (ARRs) for patients starting injectables (A) and for
patients starting or escalating to newer DMTs (B) before and on treatment:
Each line corresponds to a single patient, blue lines correspond to re-
sponders (ARR reduction after treatment), and red lines correspond to
nonresponders (ARR increase after treatment). Overall, the ARR was re-
duced from 1.9 to 1.1 while on interferon-β and glatiramer acetate (n = 92, p
< 0.001). The ARRwas reduced from 1.7 to 0.4 for newer DMTswhen used as
first medication (n = 14, p = 0.02). For newer DMTs used as 2nd- and 3rd-line
treatment, the ARR was reduced from 1.6 to 0.2 (n = 40, p = 0.003). DMT =
disease-modifying therapy.
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symptoms (n = 19), injection site reaction (n = 16), head-
aches (n = 7), myalgia and fatigue (n = 5), gastrointestinal
disturbance (n = 3), and derangements in liver function tests
and full blood count (n = 5). Side effects were reported for
18/54 (33%) who started or were escalated to newer DMTs,
of which 14 were grade 1 adverse events, and 4 were grade 2.
The most commonly reported side effects for newer DMTs
were derangements in liver function tests and full blood count
(n = 2), gastrointestinal disturbance (n = 2), myalgia and
fatigue (n = 2), and headaches (n = 1). In 5 patients, DMTs
were discontinued (n = 2) or switched (n = 3) due to side
effects (blood derangements n = 3; severe myalgia/flu-like
symptoms n = 2).
Discussion
In this UK-wide observational study of DMTs in children with
MS, we demonstrated that treatment with newer DMTs (oral
or infusions) was more effective in preventing relapses and
new or gadolinium-enhancing T2 lesions compared with in-
jectable therapies. Our results are in keeping with the first
randomized control trial of fingolimod vs interferon-β in
children.12,17 A high rate of treatment failure with injectables
has been previously reported in children, ranging from 25% to
64% across studies.18
Over the past few decades, there has been a shift toward MRI-
based measures of quantifying inflammatory activity (focal
brain lesions) being the main efficacy outcomes in adult MS
clinical trials. Lesion-related MRI markers provide an objective
measure of the underlying MS pathology and correlate with
clinical outcomes in RRMS (in particular with relapses) in the
short and medium terms.19 Our results clearly demonstrate
that children on newer DMTs took longer to new radiologic
activity compared with those on injectables. However, at 2
years after treatment initiation, although only 51% patients had
relapsed on treatment, 88% had developed new lesions on
neuroimaging, highlighting the discrepancy between clinical
activity/disease severity and radiologic features of what is
largely a highly active disease phenotype in pediatrics.
With regard tomeasures of disability, in our cohort, children had a
median EDSS score of 1.0 both at baseline before treatment
initiation and at last follow-up on treatment. EDSS score ≥2 was
observed in 9.7%of patients prior to treatment, which increased to
11.7% at last follow-up. Only a minority of children had evidence
of disability progression (defined as EDSS worsening ≥1.0 point)
on both injectables (13%) and newer DMTs (13%). A recent
North American study demonstrated that children recover better
from relapses than adults with MS20; for every 10 years of age,
there was reduced EDSS recovery by 0.15 points (p < 0.0001). In
addition, improvement inEDSS score following a relapsewas seen
in a larger proportion of children compared with adults (p =
0.006)with every 10 years of age, increasing the odds of EDSS not
improving by 1.33 times. The effect of age on both heightened
inflammation and neuronal plasticity21 influences the clinical
Figure 3Kaplan-Meier Survival Analyses for Injectables and
Newer DMTs
Kaplan-Meier survival analyses estimating the cumulative risk over 24
months of clinical relapses on treatment (A), the cumulative risk of the de-
velopment of ≥2 new T2 hyperintense and/or ≥1 gadolinium-enhancing le-
sions on brainMRI (B), and the cumulative risk of switching treatment (C) for
injectables and newer disease-modifying therapies (DMTs).
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course with better and faster recovery from relapses (evenwithout
treatments) and frequent radiologic silent activity in the absence of
clinical relapse when treatments are presumably working.
This highlights that clinical outcome measures (including
EDSS and ARR) are not a sensitive enough reflection of
disease activity alone in children, and the current practice of
waiting for the next relapse to consider treatment initiation or
escalation is unsatisfactory. A cohort study of 1,555 adult
patients with RRMS showed that initial treatment with fin-
golimod, natalizumab, or alemtuzumab was associated with a
lower risk of conversion to secondary progressive MS com-
pared with injectables.22 Given that brain atrophy is already
evident in pediatric-onset MS at clinical presentation5,23 and
is linked to disease activity,24 alternative and more sensitive
pediatric specific outcome measures are therefore necessary
either independent of or in addition to clinical outcome
measures for accurately assessing disease activity and disease
impact on the developing brain.
In our real-life clinical cohort, no pediatric-specific side effectswere
reported, and newer DMTs had a similar short-term safety, tol-
erability, and side effect profiles as in adults.25 Only 5 patients
needed to discontinue or switch DMTs due to significant adverse
events. Side effects were reported in 60%of children on injectables
and 33% of children on newer DMTs. This is somewhat reas-
suring given the concerns of medication noncompliance in ado-
lescence (reported as high as 47% with injectables26,27).
Importantly, despite the reassuring safety profile, the long-term
sequelae of both newer infusion and oral DMTs (including
alemtuzumab, ocrelizumab, and cladribine) on the developing
immune system are still unknown and will need longer-term
longitudinal studies. In addition, the cumulative risk frommultiple
DMTs, particularly in children who are likely to require treatment
for decades, needs to be considered. Fewer patients on newer
DMTs switched treatment in this study, with 20 patients (19.4%)
continuing on the same treatment despite disease activity. This
was likely due to access and availability of DMTs at the time.
In our cohort, only 2/88 children (2%) had cognitive impairment
reported in the neuropsychology testing. This is surprising given
the high rates of cognitive impairment in children reported in the
literature (30% of patients across studies28,29) and may be
explained by the short follow-up period in our cohort with cog-
nitive decline likely to occur later on in early adulthood.Data from
a population-based longitudinal cohort study from the Swedish
MS Registry evaluating cognitive outcome of 5,704 patients with
MS revealed that 300 pediatric-onset patients had higher in-
formation processing disabilities than their counterparts with
adult-onset disease, independent of age or disease duration.30
Limitations of this study include its retrospective nature, the
small number of patients included (compared to adult MS
cohorts), and the lack of long-term safety data, especially for
newer DMTs. It was also not possible to blind the clinicians
reviewing patients’ electronic records and collecting outcome
data to the DMT they received, which may have introduced
measurement bias. Furthermore, as patients often switched
treatment horizontally across categories (e.g., one injectable to
another) or vertically (i.e., escalating from injectable to newer
DMT), the different mechanisms of action of various drugs and
duration to achieve effectiveness may have introduced further
bias. Despite these limitations, our findings are generalizable to
a broad range of patients with pediatric MS across diverse
geographic areas in the United Kingdom. In addition, our
findings corroborate with those from those in differing geo-
graphical locations such as the United States despite different
health care systems, practice preferences, and access to certain
DMTs. Furthermore, given that pediatric MS randomized
controlled trials have ongoing major recruitment challenges
and largely focus on establishing drug efficacy at the population
level, real-world observational cohort studies such as ours can
provide a valuable alternative in analyzing the multiple factors
shaping treatment response andMS clinical outcome in clinical
practice.
Our study adds weight to the argument for an imminent shift
in practice toward the use of newer, more efficacious DMTs in
the first instance. As relapses are the highest and MRI activity
continues on DMTs, and this can impact on brain atrophy,
which is most rapid in the first few years after onset of pedi-
atric MS, this time period may present a critical therapeutic
window for the use of highly effective therapies.
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